TD Cowen's Buy Rating#
TD Cowen has reiterated a Buy rating for BridgeBio Pharma (NASDAQ:BBIO), setting a price target of $95.00. Currently, the stock is trading at $70.84, indicating significant upside potential. Analysts have set targets as high as $157, suggesting that there is room for growth in the company's stock value.
Patent Settlement and Market Position#
The firm noted that a recent settlement regarding Pfizer's tafamidis, which is set to expire in June 2031, gives BridgeBio a competitive edge. This settlement allows BridgeBio approximately 7.5 to 8 years to launch its product, Attruby, before facing competition from generic versions of tafamidis. While generic competition may affect new prescriptions, it is expected to only slightly slow revenue growth rather than cause an immediate decline.
Analyst Confidence#
Several analysts, including those from RBC Capital, William Blair, Mizuho, and Piper Sandler, have also reaffirmed their positive outlook on BridgeBio, with price targets ranging from $100 to $111. This renewed confidence follows the resolution of a legal dispute over the tafamidis patent, which has strengthened analysts' views on BridgeBio's future prospects.
Public Health Initiatives#
In addition to its legal and market developments, BridgeBio Pharma has launched a national awareness campaign for ATTR-CM, a progressive heart disease. Featuring actor Morgan Freeman, the campaign titled "Don’t Pass On Your Heart Health" aims to raise awareness of this condition, especially among individuals over 55. This initiative underscores BridgeBio's commitment to public health and its proactive approach in addressing heart health issues.